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Background: Epidermal hyperplasia is a histological hallmark observed in both atopic dermatitis (AD)
and psoriasis, although the clinical features and the underlying immunological disorders of these dis-
eases are different. We previously showed that periostin, a matricellular protein, plays a critical role in
epidermal hyperplasia in AD, using a mouse model and a 3-dimensional organotypic coculture system. In
this study, we explore the hypothesis that periostin is involved in epidermal hyperplasia in psoriasis.
Methods: To examine expression of periostin in psoriasis patients, we performed immunohistochemical
analysis on skin biopsies from six such patients. To investigate periostin's role in the pathogenesis of
psoriasis, we evaluated periostin-deﬁcient mice in a psoriasis mouse model induced by topical treatment
with imiquimod (IMQ).
Results: Periostin was substantially expressed in the dermis of all investigated psoriasis patients.
Epidermal hyperplasia induced by IMQ treatment was impaired in periostin-deﬁcient mice, along with
decreased skin swelling. However, upon treatment with IMQ, periostin deﬁciency did not alter inﬁl-
tration of inﬂammatory cells such as neutrophils; production of IL-17, 22, or 23; or induction/
expansion of IL-17e and IL-22eproducing group 3 innate lymphoid cells.
Conclusions: Periostin plays an important role during epidermal hyperplasia in IMQ-induced skin
inﬂammation, independently of the IL-23eIL-17/IL-22 axis. Periostin appears to be a mediator for
epidermal hyperplasia that is common to AD and psoriasis.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Atopic dermatitis (AD) and psoriasis are the most common in-
ﬂammatory skin diseases.1 The clinical skin features of AD are
highly pruritic eczematous erythematous plaques. In contrast,
psoriasis is characterized by well-demarcated plaques with thick,
nonadherent, silvery-white scales. Erythematous plaques andemistry, Department of Bio-
shima, Saga 849-8501, Japan.
ra).
ety of Allergology.
rgology. Production and hosting by Elsscales appear in both AD and psoriasis, but the features of the scales
are different in these two diseases. In spite of the differing clinical
features in AD and psoriasis, epidermal hyperplasia (acanthosis) is a
histological similarity observed in these diseases.1 It is assumed
that epidermal hyperplasia provides a basis for supplying more
massive proinﬂammatory mediators from keratinocytes. However,
there is no satisfactory explanation of why epidermal hyperplasia is
common in both diseases.
The underlying immunological disorders of AD and psoriasis are
also signiﬁcantly different. In AD, type 2 immune responses are
dominant, particularly in the acute lesions, and type 1 responses
are involved in the chronic stage.2 In contrast, in the pathogenesisevier B.V. All rights reserved.
Table 1
Psoriasis patient information.
Patient Age Sex Disease
duration (mo.)
Biopsy Clinical signs Diagnosis
1 40 M 2 Mandible Scales, erythema Psoriatic
arthritis
2 71 M 4 Palm Scattered plaques Psoriasis
vulgaris
3 56 F 5 Lower leg Multiple eruptions Psoriasis
vulgaris
4 58 F 6 Knee Multiple eruptions Psoriasis
vulgaris
5 62 M 120 Lower leg Multiple plaques,
erythema, scale
Psoriasis
vulgaris
6 77 F 180 Forearm Erythema Psoriasis
vulgaris
K. Arima et al. / Allergology International 64 (2015) 41e4842of psoriasis, TNF and IFN-a activates dendritic cells (DCs) followed
by activation of type 1, type 17, and type 22 immune pathways.3 For
psoriasis, the IL-23eIL-17/IL-22 axis is critical for epidermal hy-
perplasia. Deﬁciency or blockage of IL-17, IL-22, or their receptors
down-regulated epidermal hyperplasia in psoriasis model mice.4e7
It has been assumed that keratinocyte proliferation factors such as
IL-6 and tumor growth factor a, abundantly expressed in skin tis-
sues of psoriasis patients, play pivotal roles in epidermal hyper-
plasia.8 Accordingly, it has been postulated that epidermal
hyperplasia by IL-23 is dependent on IL-6.9
Periostin, an extracellular matrix protein belonging to the fas-
ciclin family, has been shown to be essential to the process of
remodeling during tissue/organ development/repair and inﬂam-
mation.10,11 Periostin functions as a matricellular protein in cell
activation by binding to receptors on the cell surface, thereby
exerting its biological activities.We have shown that periostin plays
a critical role in allergic skin inﬂammation induced by topical
treatment with house dust mite extract (HDM) using periostin-
deﬁcient mice.12,13 Deﬁciency of periostin caused impaired
epidermal hyperplasia in addition to down-regulated skin inﬂam-
mation. We furthermore revealed how periostin derived from ﬁ-
broblasts causes proliferation and differentiation of keratinocytes
using a 3-dimensional organotypic coculture system of keratino-
cytes and ﬁbroblasts.12,14 Periostin secreted from ﬁbroblasts and IL-
1a derived from keratinocytes synergistically act on ﬁbroblasts to
induce production of IL-6 by activating the NF-kB pathway. IL-6
secreted from ﬁbroblasts acts on keratinocytes, inducing prolifer-
ation and differentiation. Thus, the epithelialemesenchymal
interaction involving periostin represents a mechanism capable of
regulating proliferation and differentiation of keratinocytes in AD.
Given that epidermal hyperplasia is a common histological char-
acteristic in AD and psoriasis and that periostin is critical for the in-
duction of epidermal hyperplasia in AD, we hypothesized that
periostin might be involved in epidermal hyperplasia in psoriasis as
well. Our recent ﬁnding that serum periostin levels in psoriasis pa-
tients were lower than those of AD patients, but signiﬁcantly higher
than those of normal donors supports this idea.15 In this study, we
examined theexpressionofperiostin inpsoriasis patients andapplied
periostin-deﬁcientmice to a psoriasismodel using imiquimod (IMQ),
an agonist of toll-like receptor (TLR) 7 andTLR8.We found substantial
expression of periostin in all investigated psoriasis patients in a
pattern similar to AD patients and that epidermal hyperplasia is
decreased in IMQ-treated periostin-deﬁcient mice. These results
provide clear evidence that periostin is a mediator for the formation
of epidermal hyperplasia common to both AD and psoriasis.
Methods
Human skin tissue specimens
Skin tissues examined for histology were obtained from four
normal donors, ﬁve patients with psoriasis vulgaris, and one patient
with psoriatic arthritis (Table 1). We primarily diagnosed psoriasis
based on clinical manifestations and histopathological ﬁndings.16
The six psoriasis patients examined for histology were from ages
40 to 77, three males and three females. No patients had comorbid-
ities known to up-regulate periostin expression. A normal facial skin
section was obtained from a non-psoriatic patient. All patient sam-
ples were taken after a medication-free period of at least twoweeks.
Mice
Periostin-deﬁcient (Postn/) mice prepared as previously
described (129SvJ; C57BL/6 background, Ref. 17) were backcrossed
to BALB/c mice (Japan SLC, Shizuoka, Japan), and N7eN8mice wereused. Twelve-week-old Postn/ mice and their wild-type or
Postnþ/ littermates as control were compared.
Model mice of psoriasis
Model mice of psoriasis using IMQwere generated as previously
described, with minor modiﬁcations.4 A daily dose of 30 mg of 5%
IMQ cream (Beselna cream; Mochida Pharmaceutical Co. Ltd.,
Tokyo, Japan) or control cream (hydrophilic petrolatum or Vaseline,
Nikko Pharmaceutical Co. Ltd., Gifu, Japan) was applied to each ear
for seven days. In Fig. 3G, IMQwas applied only to the right ear. The
ear thickness was measured every day using calipers (Ozaki MFG,
Tokyo, Japan). The difference in ear thickness between day 0 and
every subsequent day was expressed as ear swelling.
Histology
Exiced ear lobes were ﬁxed in 10% buffered formalin and
embedded in parafﬁn. Deparafﬁnized sections were stained using
hematoxylin and eosin (H&E). Epidermal thickness was measured
at 10 random points per sample and expressed as an average value.
Immunohistochemical staining for myeloperoxidase (MPO, poly-
clonal rabbit anti-human myeloperoxidase, Dako, Glostrup,
Denmark) and periostin (rabbit anti-periostin IgG) was performed
as described previously.18
Real-time quantitative PCR
Total mRNA was extracted from a half-cut ear, isolated using
RNAiso Plus (Takara Bio, Otsu, Japan), and reverse-transcribed
with the ReverTra Ace (Toyobo, Osaka, Japan). Quantitative PCR
analyses were performed on a StepOnePlus real-time PCR System
(Life Technologies, Carlsbad, CA, USA) using the Thunderbird
SYBR qPCR mix (Toyobo). PCR primers were IL-1a (Il1a), forward
primer, 50-TTGGTTAAATGACCTGCAACA-30, and reverse primer, 50-
GAGCGCTCACGAACAGTTG-30; IL-6 (Il6), forward primer, 50-GCTAC
CAAACTGGATATAATCAGGA-30 and reverse primer, 50-CCAGG-
TAGCTATGGTACTCCAGAA-30; IL-17A (Il17a), forward primer, 50-
TGTGAAGGTCAACCTCAAAGTCT-30, and reverse primer, 50-GAGG-
GATATCTATCAGGGTCTTCAT-30; IL-17F (Il17f), forward primer, 50-
CCCAGGAAGACATACTTAGAAGAAA-30 and reverse primer, 50-GC
AAGTCCCAACATCAACAG-30; IL-22 (Il22), forward primer, 50-GCT
CAGCTCCTGTCACATCA-30, and reverse primer, 50-AATCGCCTT-
GATCTCTCCAC-30; IL-23p19 (Il23a), forward primer, 50-TCCCTAC-
TAGGACTCAGCCAAC-30 and reverse primer, 50-AGAACTCA
GGCTGGGCATC-30; IL-36a (Il36a), forward primer, 50-TGCCCACT-
CATTCTGACCCA-30, and reverse primer, 50-GTGCCACA-
GAGCAATGTGTC-3’; IL-36b (Il36b), forward primer,
K. Arima et al. / Allergology International 64 (2015) 41e48 4350-CTTCGATCCCAGAGACAAGACT-30 and reverse primer, 50-ATTC
GGTTCCCACATTTGAA-30; CXCL2/MIP-2a (Cxcl2), forward primer,
50-CCTGGTTCAGAAAATCATCCA-30, and reverse primer, 50-CTTCC
GTTGAGGGACAGC-30; S100A9 (S100a9), forward primer, 50-
CACCCTGAGCAAGAAGGAAT-30 and reverse primer, 50-TGTCATT-
TATGAGGGCTTCATTT-30; and GAPDH (Gapdh), forward primer, 50-
TCACCACCATGGAGAAGGC-30, and reverse primer, 50-GCTAAG-
CAGTTGGTGGTGCA-30. Threshold cycles of primer probes were
normalized to a housekeeping gene, Gapdh.
Flow cytometry
Submandibular lymph nodes were consistently swollen at day 7
amongmicewith ears treatedwith IMQ. Lymph node samples were
minced through a 40-mm nylon mesh (Cell Strainer, BD Biosciences,
Franklin Lakes, NJ, USA) to obtain single-cell suspensions. Cells
were rested in RPMI supplemented with 10% fetal calf serum
overnight, and 2  106 cells/200 ml were stimulated with 50 ng/ml
phorbol 12-myristate 13-acetate and 2 mg/ml ionomycin (Sigma-
Aldrich, St. Louis, MO, USA) together with monensin (BioLegend,
San Diego, CA, USA) for 6 h. Cells were stained with anti-CD3 3
followed by intracellular staining using monoclonal antibodies
(mAbs) PE-conjugated antieIL-17A or antieIL-22 (eBioscience, San
Diego, CA, USA) after ﬁxation and permeabilization with FIX &
PERM reagent (Life Technologies). Samples were acquired on aNormal skin Patie
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Fig. 1. Histological views of skin tissues of psoriasis patients. Histological sections stained
or psoriasis vulgaris patients (Patient #3; B, E, H, and Patient #5; C, F, I). Bars represent 20
disease duration, respectively.FACSCalibur (BD Biosciences) and analyzed using FlowJo software
(TreeStar Inc., Ashland, OR, USA).
Enzyme-linked immunosorbent assay (ELISA)
Mouse embryonic ﬁbroblasts were cultured in DMEM supple-
mented with 10% FCS at 1105 cells/ml overnight. The mediumwas
then replaced with Opti-MEM I (Life Technologies) and stimulated
with mouse recombinant IL-17 (Sigma-Aldrich), IL-21, IL-22, IL-36b
(R&D Systems, Minneapolis, MN, USA), or IL-13 (PeproTech, Rocky
Hill, NJ, USA) at 50 ng/ml for 24 h. The ELISA analysis for periostin in
the supernatants was performed as described previously.14
Statistical analyses
Data are presented as mean ± standard deviations and analyzed
by Student's t-test or repeated measures two-way analysis of
variance (ANOVA), followed by Bonferroni's post-hoc tests. Data
were analyzed using Prism (GraphPad, La Jolla, CA, USA) with the
signiﬁcance level a at 0.05.
Experiment approval
Animal experiments were undertaken following the guidelines
for care and use of experimental animals of the Japanese Associationnt #3 Patient #5
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Fig. 2. Macroscopic changes of IMQ-treated mice. (A) Ear swelling of Vaseline-
treated Postnþ/ mice (n ¼ 4), IMQ-treated Postnþ/þ or Postnþ/ mice (n ¼ 24), and
IMQ-treated Postn/ mice (n ¼ 15) were depicted. Ear thickness before treatment was
subtracted from the individual ear thickness. Data are presented as mean ± s.d. ***:
p < 0.001, ****: p < 0.0001. (B) Representative posterior views of ears of Vaseline-
treated Postnþ/ mice and IMQ-treated Postnþ/ and Postn/ mice for both genders.
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by the Institutional Animal Care and Use Committee of SagaMedical
School. Human studies were performed under protocols approved
by the Ethics Committees of Juntendo University.
Results
Expression of periostin in psoriatic skin tissues
Expression of periostin protein was analyzed by immunohisto-
chemistry on skin tissues derived from ﬁve patients with psoriasis
vulgaris and one patient with psoriatic arthritis. The clinical features
of these patients are listed in Table 1. All investigated samples
showed enhanced expression of periostin compared with normal
donors (Fig. 1). Periostin was exclusively expressed in the dermis of
the patients, particularly at the epidermal border, similar towhat has
been observed in AD patients.12 These results demonstrate that
periostin is deposited in skin tissues of psoriasis patients in a pattern
similar to that of AD, supporting our hypothesis that periostin may
play some role in the pathogenesis of psoriasis, as it is known to AD.
Involvement of periostin in skin swelling in IMQ-treated mice
To investigate the role of periostin in the pathogenesis of pso-
riasis, we employed topical application of IMQ, a well-known
mouse model of psoriasis.4 Upon IMQ treatment, the ears of the
mice started to swell the ﬁrst day after initiation, and the swelling
continuously increased until day 7 (Fig. 2A). The ears treated with
IMQ showed erythema, scales, and hair loss (Fig. 2B). When we
applied IMQ treatment to periostin-deﬁcient littermates, ear
swelling was signiﬁcantly decreased (Fig. 2A, repeated measures
two-way analysis of variance with Bonferroni's post-hoc test,
p < 0.0001). The macroscopic featuresd such as erythema, scales,
and hair loss d were milder in periostin-deﬁcient mice than in
control mice (Fig. 2B). There were no obvious sex-related differ-
ences in these features nor in ear swelling (Fig. 2B and data not
shown). These results suggest that periostin is required during
IMQ-induced skin inﬂammation in mice.
Involvement of periostin in epidermal hyperplasia in IMQ-treated
mice
We then histologically analyzed skin tissues from IMQ-treated
mice. The epidermis in the IMQ-treated control mice showed hy-
perplasia (acanthosis), hyperkeratosis, and parakeratosis charac-
terized by retention of nuclei in the corniﬁed layer, similar to
psoriasis patients (Fig. 3A, B and D). Massive inﬁltration of neu-
trophils was observed in the dermis and were present in the
epidermis like Munro's microabscesses in psoriasis patients (Fig. 3E
and F). Lymphocytes and macrophages also signiﬁcantly inﬁltrated
the dermis. Topical treatment with IMQ transiently enhanced per-
iostin expression extensively in the dermis at day 3, as observed in
the psoriasis patients (Fig. 3G, day (d) 3, right), whereas periostin
was only slightly expressed at the borders of the epidermis and
dermis in non-treated mice or non-treated ears (Fig. 3G, d0 and 3,
left). Epidermal thickness upon treatment with IMQ in periostin-
deﬁcient mice was signiﬁcantly decreased (71.2%, p < 0.0001,
Fig. 3C and D). Inﬁltration of neutrophils (MPOþ cells) in the
epidermis showed a tendency to decrease, but the difference was
not statistically signiﬁcant (Fig. 3F and data not shown). The
observed inﬁltration of neutrophils and macrophages in the dermis
was similar to that found in the control mice. These results suggest
that periostin plays an important role in the process of epidermal
thickness but not in the inﬁltration of inﬂammatory cells in the
IMQ-treated mice.Periostin is not required for IMQ-induced production of
proinﬂammatory cytokines/chemokines
It is known that type 1, type 17, and type 22 immune responses
are triggered by TNF and IFN-a in the pathogenesis of psoriasis.3 In
particular, analyses of the model mice using IMQ show the critical
role of the IL-23eIL-17/IL-22 axis in skin inﬂammation.4e7 More-
over, it has been demonstrated that IL-36, a member of the IL-1
family, is involved in the pathogenesis of psoriasis by interacting
with DC-keratinocyte cross-talk.19 We then examined the role of
periostin in producing IMQ-induced proinﬂammatory mediators.
IMQ treatment increased expression of all investigated proin-
ﬂammatory cytokines and chemokines, including Il1a, Il6, Il17a,
Il17f, Il22, Il23a, Il36a, Il36b, and Cxcl2 as well as S100a9, a neutrophil
marker (Fig. 4). Expression of all of these proinﬂammatory cyto-
kines and chemokines at mRNA level was not signiﬁcantly altered
in periostin-deﬁcient mice. These results demonstrate that peri-
ostin is mostly dispensable for IMQ-induced production of proin-
ﬂammatory cytokines/chemokines at mRNA level. However, we
Fig. 3. Histological changes of IMQ-treated mice. Histological sections stained with H&E (AeC) or immunostained for MPO (E, F) of Vaseline-treated (A) or IMQ-treated (B, C, E, F)
Postnþ/ (A, B, E), or Postn/ (C, F) mice. (D) Histological epidermal thickness of mice used in Fig. 2A. (G) Histological sections immunostained for periostin of IMQ-treated (right ear
only) wild-type mice at days (d) 0, 3, and 7. Left ears were left untreated in this experiment. Bars represent 50 mm (AeC, G) and 20 mm (E, F). ****: p < 0.0001.
K. Arima et al. / Allergology International 64 (2015) 41e48 45noted a consistent decrease, albeit not statistically signiﬁcant, in
mRNA expression of Il17f and Il22 in independent sets of experi-
ments (Fig. 4 and data not shown).
Periostin is dispensable for IMQ-induced activation/expansion of
group 3 innate lymphoid cells (ILC3)
Recently, the signiﬁcance of innate cells, such as gd T cells and
ILC3, has emerged as IL-17Ae and IL-22eproducing cells in various
inﬂammatory diseases/states.5,7 We next investigated the involve-
ment of periostin in induction/expansion of IL-17Ae and IL-
22eproducing gd T cells and ILC3 by IMQ. We stained either IL-17A
or IL-22 on expanded cells within the draining lymph nodes. Both IL-
17Ae and IL-22eproducing cells in the CD3- fraction that contains
ILC3 signiﬁcantly increased, whereas those of the CD3þ fraction that
contains ab and gd T cells only slightly increased in the IMQ-treated
mice (Fig. 5). The proportions of IL-17Ae and IL-22eproducing cells
in the CD3- fraction were not signiﬁcantly changed in periostin-
deﬁcient mice. These results suggest that periostin does not affect
induction/expansion of IL-17Ae or IL-22eproducing ILC3 by IMQ, at
least in the peripheral lymphoid tissues.
Failure to induce periostin expression by psoriasis-associated
proinﬂammatory mediators
We have shown that IL-4 and/or IL-13, signature type 2 cyto-
kines, induce expression of periostin in allergic inﬂammation/dis-
eases.12,18,20 In addition to IL-4 and IL-13,various factorsdTGF-b 1,2, and 3, bone morphogenetic proteins (BMP) 2 and 4, vascular
endothelial growth factor, connective tissue growth factor 2,
vitamin K, valsartan (an angiotensin II antagonist), and IL-3 and
-6dare known to trigger periostin expression.10 We examined the
possibility that any of the psoriasis-associated cytokines would
induce periostin expression, resulting in periostin being deposited
in the skin tissues of psoriasis patients. However, none of the fac-
tors testeddIL-17, -21, -22, and 36bdinduced expression of per-
iostin in ﬁbroblasts (Fig. 6). These results suggest the possibility
that some factor(s) expressed in psoriasis patients other than IL-17,
-21, -22, and 36b or the combination of multiple factors may
induce periostin expression.
Discussion
In this study, we investigated both the expression and functional
requirement of periostin in the pathogenesis of psoriasis. By using
immunohistochemical analysis, we demonstrated that periostin is
highly deposited in the dermis of psoriasis patients (Fig. 1).
Accordingly, we recently found that serum periostin levels in pso-
riasis patients were signiﬁcantly higher than those in normal do-
nors.15 We conﬁrmed by immunohistochemistry that IMQ
treatment induced at least a transient deposit of periostin in the
dermis as observed in psoriasis patients (Figs.1 and 3G). From these
ﬁndings, we assume that the use of periostin-deﬁcient mice in the
IMQ-induced psoriasis-like dermatitis model corresponds to a
study to investigate the effects of both basal and IMQ-induced
periostin in this mouse model.
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Fig. 4. Periostin expression does not affect IMQ-induced skin inﬂammation in mice. End-point (d7) quantitative RT-PCR analyses of various psoriasis-associated genes in mouse
ears are shown in Fig. 2A. None of these genes showed a statistical signiﬁcant difference between IMQ-treated control and Postn/ mice.
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Fig. 6. Failure of induction of periostin expression by psoriasis-associated cyto-
kines. Mouse embryonic ﬁbroblasts were stimulated with 50 ng/ml indicated cyto-
kines or left unstimulated () for 24 h. Amount of periostin in the supernatants was
measured using ELISA.
K. Arima et al. / Allergology International 64 (2015) 41e48 47We found by the analyses using periostin-deﬁcient mice that
periostin is important for epidermal hyperplasia, a common feature
of both psoriasis and AD. This result raised the possibility that
periostin would be a common mediator for epidermal hyperplasia
in psoriasis and AD. Multiple lines of evidence have accumulated
suggesting that periostin acts as a matricellular protein inducing
cell proliferation such as keratinocytes in wound repair and ma-
lignant cells via the signal transduction pathways including FAK,
PI3-kinase, Akt, ERK, NF-kB, and STAT3.10,11 It is reasonable to as-
sume that periostin expressed in skin tissues of psoriasis patients
acts on keratinocytes as a matricellular protein inducing keratino-
cyte proliferation. We previously demonstrated that administration
of the antibodies against aV integrin down-regulated keratinocyte
proliferation in the AD model mice and in the 3-dimentional
organotypic coculture system.12 We furthermore showed that in-
duction of IL-6 expression in ﬁbroblasts is one of the mechanisms
by which periostin promotes keratinocyte proliferation.14 Collec-
tively, it can be assumed that IL-6 production by the interaction
between periostin and aV integrin on ﬁbroblasts could be one of the
mechanisms underlying epidermal hyperplasia in pathological
status. However, IL-6 expression in the skin was invariant in IMQ-
treated control and periostin-deﬁcient mice (Fig. 4). This may be
due to spatiotemporal mismatches between the in vivo IL-6 actions
on keratinocytes and our analyses, which were performed only at
the speciﬁed times and used the whole skin tissues. Alternatively,
some effects of periostin on keratinocytes other than inducing IL-6
production may be important for keratinocyte proliferation in the
IMQ-treated mice.
In contrast to epidermal thickness, inﬁltration of inﬂammatory
cells such as neutrophils, production of IL-17, -22, and -23, and
induction/expansion of IL-17e and IL-22eproducing ILC3 induced
by IMQ were not altered in periostin-deﬁcient mice (Figs. 4 and 5).
These inﬂammatory changes are likely due to the more immediate
effects of IMQ, and the contribution of periostin is very limited or
negligible. This result contrasts with our previous ﬁnding that type
2 immune responses are impaired in HDM-treated periostin-deﬁ-
cient mice.12 These contrasting results clearly indicate that the
involvement of periostin in the pathogenesis of AD and psoriasis
differs in that acceleration of inﬂammatory responses by periostin
observed in ADmodel mice is not involved in psoriasis model mice.
Moreover, the present results suggest that the mechanisms ofepidermal hyperplasia and inﬂammatory responses are uncoupled
in the IMQ-treated mice. It has been proposed that the IL-23eIL-17/
IL-22 axis is critical for epidermal hyperplasia in psoriasis.4e7
However, our results demonstrate the presence of an IL-23eIL-17/
IL-22 axiseindependent pathway for epidermal hyperplasia in
psoriasis.
We examined which psoriasis-associated cytokinedIL-17, -21,
-22, and 36bdmight induce periostin expression in ﬁbroblasts,
but none of these factors exerted such effect (Fig. 6). Some other
factors expressed in psoriasis patients, or a combination of any of
these factors, may induce periostin expression. Thus far, various
factorsdTGF-b1, 2, and 3, BMP2 and 4, vascular endothelial growth
factor, connective tissue growth factor 2, vitamin K, valsartan, and
IL-3 -4, -6, and 13dare known to induce periostin expression.10
On the other hand, we and others have demonstrated that peri-
ostin is expressed in various inﬂammatory diseases/states such as
AD,12,15 IgG4-related sclerosing sialadenitis,21 eosinophilic otitis
media,22 allergic rhinitis and chronic rhinosinusitis,23 idiopathic or
drug-induced pulmonary ﬁbrosis,24,25 scleroderma,26 and prolifer-
ative diabetic retinopathy.27,28 It has been largely undetermined
what triggers periostin expression on each of these pathological
states. Moreover, the molecular mechanism of periostin expression
induced by various factors has remained unclear. Further studies
aiming at clarifying these points are needed.
In conclusion, we demonstrate that periostin is highly expressed
in the dermis of psoriasis patients, as it is in AD patients, and that
periostin plays an important role in IMQ-induced epidermal hy-
perplasia in mice. These results provide us with strong evidence
that periostin is a mediator for epidermal hyperplasia common to
both AD and psoriasis.Acknowledgments
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